NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Ascending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50742-0184-25 | 50742-0184 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 30, 2020 | In Use | |
50742-0519-02 | 50742-0519 | cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | July 30, 2020 | In Use | |
50742-0520-05 | 50742-0520 | cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | July 30, 2020 | In Use | |
70934-0786-90 | 70934-0786 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | July 30, 2020 | In Use | ||
55150-0386-01 | 55150-0386 | CARBOPLATIN | CARBOPLATIN | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug. 3, 2020 | In Use | |
70255-0025-05 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug. 3, 2020 | In Use | |
70255-0025-06 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug. 3, 2020 | In Use | |
00469-0625-99 | 00469-0625 | enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 4, 2020 | In Use | |
00469-0725-60 | 00469-0725 | enzalutamide | Xtandi | 80.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 4, 2020 | In Use | |
00469-1725-56 | 00469-1725 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 4, 2020 | In Use | |
73535-0208-01 | 73535-0208 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug. 5, 2020 | In Use | |
00173-0896-01 | 00173-0896 | Belantamab | Blenrep | 50.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | BCMA | Intravenous | Aug. 5, 2020 | June 30, 2024 | In Use |
10019-0982-01 | 10019-0982 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug. 7, 2020 | In Use | |
10019-0984-01 | 10019-0984 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug. 7, 2020 | In Use | |
70518-2829-00 | 70518-2829 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 7, 2020 | In Use | ||
70934-0580-20 | 70934-0580 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 11, 2020 | In Use | |
71205-0403-07 | 71205-0403 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 13, 2020 | Aug. 31, 2023 | No Longer Used |
59651-0299-60 | 59651-0299 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 14, 2020 | In Use | ||
59651-0300-30 | 59651-0300 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 14, 2020 | In Use | ||
59651-0300-90 | 59651-0300 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 14, 2020 | In Use | ||
72603-0107-01 | 72603-0107 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 17, 2020 | In Use | |
43598-0262-02 | 43598-0262 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Aug. 17, 2020 | In Use | ||
69448-0005-38 | 69448-0005 | Carboplatin | Paraplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug. 17, 2020 | In Use | |
70934-0634-82 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 18, 2020 | Aug. 31, 2023 | In Use |
77651-1112-01 | 77651-1112 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 19, 2020 | In Use | |
77651-1113-02 | 77651-1113 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 19, 2020 | In Use | |
69539-0152-30 | 69539-0152 | Toremifene citrate | Toremifene citrate | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 20, 2020 | In Use | ||
70518-2115-02 | 70518-2115 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 21, 2020 | In Use | |
16729-0486-01 | 16729-0486 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 24, 2020 | In Use | |
00574-0792-01 | 00574-0792 | pilocarpine hydrchloride | pilocarpine hydrchloride | 5.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Cholinergic Agonist | Oral | Aug. 24, 2020 | In Use | |
64842-0727-09 | 64842-0727 | CEDAZURIDINE and DECITABINE | INQOVI | 100.0 mg/1, 35.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog + CDA Inhibitor | Oral | Aug. 25, 2020 | In Use | |
60760-0715-21 | 60760-0715 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 25, 2020 | In Use | |
71205-0421-42 | 71205-0421 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 25, 2020 | In Use | |
69539-0158-01 | 69539-0158 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
69539-0159-01 | 69539-0159 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
69539-0157-01 | 69539-0157 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
72205-0063-01 | 72205-0063 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
72205-0062-01 | 72205-0062 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
72205-0061-01 | 72205-0061 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
70518-2864-00 | 70518-2864 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 28, 2020 | In Use | |
67457-0996-20 | 67457-0996 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Aug. 28, 2020 | In Use | |
67457-0997-40 | 67457-0997 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Aug. 28, 2020 | In Use | |
70934-0634-95 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 31, 2020 | May 31, 2025 | In Use |
59572-0730-14 | 59572-0730 | azacitidine | ONUREG | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
59572-0740-14 | 59572-0740 | azacitidine | ONUREG | 300.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
70756-0816-22 | 70756-0816 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
70756-0815-60 | 70756-0815 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
72611-0716-01 | 72611-0716 | Dexrazoxane for Injection | Dexrazoxane | 500.0 mg/50mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Sept. 1, 2020 | In Use | |
72205-0050-30 | 72205-0050 | Toremifene citrate | Toremifene citrate | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Sept. 2, 2020 | In Use | ||
00781-3497-75 | 00781-3497 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 2, 2020 | Feb. 29, 2024 | No Longer Used |
72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 4, 2020 | In Use | |
72064-0210-12 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-60 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-90 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
00143-9384-01 | 00143-9384 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 8, 2020 | In Use | |
67184-0540-01 | 67184-0540 | Fosaprepitant dimeglumine | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 8, 2020 | In Use | |
49315-0008-03 | 49315-0008 | Doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 14, 2020 | In Use | |
49315-0009-07 | 49315-0009 | Doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 14, 2020 | In Use | |
70710-1530-01 | 70710-1530 | Doxorubicin hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 14, 2020 | In Use | |
70710-1531-01 | 70710-1531 | Doxorubicin hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 14, 2020 | In Use | |
43598-0344-31 | 43598-0344 | Imatinib | Imatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 15, 2020 | In Use | |
43598-0345-31 | 43598-0345 | Imatinib | Imatinib | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 15, 2020 | In Use | |
50242-0210-86 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 15, 2020 | Feb. 11, 2022 | In Use |
80425-0074-04 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-01 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-02 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-03 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-05 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
50242-0103-01 | 50242-0103 | polatuzumab vedotin | POLIVY | 30.0 mg/1.88mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Sept. 18, 2020 | In Use | |
70518-2894-00 | 70518-2894 | Methylprednisolone Acetate | Methylprednisolone Acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Soft Tissue | Sept. 22, 2020 | In Use | |
70518-2676-01 | 70518-2676 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 22, 2020 | In Use | |
42291-0085-90 | 42291-0085 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Sept. 23, 2020 | In Use | ||
70518-2895-00 | 70518-2895 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 25, 2020 | In Use | |
64380-0970-25 | 64380-0970 | Hydrocortisone | Hydrocortisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 25, 2020 | In Use | |
64380-0971-06 | 64380-0971 | Hydrocortisone | Hydrocortisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 25, 2020 | In Use | |
64380-0972-06 | 64380-0972 | Hydrocortisone | Hydrocortisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 25, 2020 | In Use | |
68180-0690-01 | 68180-0690 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 25, 2020 | Jan. 31, 2024 | No Longer Used |
70934-0448-95 | 70934-0448 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 26, 2020 | In Use | |
68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sept. 29, 2020 | In Use | |
54288-0106-03 | 54288-0106 | Melphalan Hydrochloride | Melphalan | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Sept. 30, 2020 | In Use | ||
66993-0844-35 | 66993-0844 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 1, 2020 | In Use | |
66993-0845-35 | 66993-0845 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 1, 2020 | In Use | |
66993-0846-35 | 66993-0846 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 30.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 1, 2020 | In Use | |
42291-0505-01 | 42291-0505 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 5, 2020 | In Use | |
67457-0920-05 | 67457-0920 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct. 12, 2020 | May 31, 2021 | In Use | |
68001-0442-26 | 68001-0442 | cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Oct. 19, 2020 | In Use | |
68001-0443-27 | 68001-0443 | cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Oct. 19, 2020 | In Use | |
68001-0444-32 | 68001-0444 | cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Oct. 19, 2020 | In Use | |
70934-0798-30 | 70934-0798 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct. 19, 2020 | In Use | ||
70518-2914-00 | 70518-2914 | Methylprednisolone Acetate | Methylprednisolone Acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Oct. 21, 2020 | In Use | |
70518-2915-00 | 70518-2915 | Methylprednisolone acetate | Methylprednisolone acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Oct. 21, 2020 | In Use | |
13668-0591-81 | 13668-0591 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0591-82 | 13668-0591 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0592-84 | 13668-0592 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0592-86 | 13668-0592 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0593-86 | 13668-0593 | APREPITANT | APREPITANT | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0594-87 | 13668-0594 | APREPITANT | APREPITANT | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oct. 21, 2020 | In Use | |||
70518-2916-00 | 70518-2916 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 21, 2020 | July 19, 2021 | No Longer Used |
16729-0240-03 | 16729-0240 | FOSAPREPITANT | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Oct. 22, 2020 | In Use | |
71288-0116-11 | 71288-0116 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Oct. 23, 2020 | In Use |
Found 10,000 results in 10 milliseconds — Export these results